Amneal Pharmaceuticals Stock - Analyst consensus and risk profile on a quiet news day

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 16:50 CET. Details in the imprint.

Amneal Pharmaceuticals (US03168L1052) is trading through the weekend without a new earnings release, SEC filing or rating change from the major houses. In this quiet setting, investors are looking instead at the latest analyst commentary and risk metrics around the Nasdaq-listed stock.

What current risk metrics show

With no fresh headlines, the spotlight shifts to how the market is pricing Amneal’s risk and growth prospects. On 06/18/2026, third-party data providers showed the stock at about $16.21 with a market capitalization near $5.17 billion.

One recent risk screen assigns Amneal a score of 8.42 on its internal scale, placing it 26th out of 157 names in the pharmaceuticals cohort and signaling above-average but not extreme risk for the sector. The same assessment cites a beta of 1.31 versus the broad market, pointing to higher-than-average volatility in both up and down phases.

Analyst and market sentiment snapshot

Looking beyond pure volatility, several analysts frame Amneal less as a classic volume-driven generics producer and more as a value-tilted play that is pivoting toward higher-margin specialty drugs and complex biosimilars. That shift is central to most recent research views.

Market commentary notes that Amneal stock traded at a forward price-to-earnings multiple historically below the broader health care group, often in the high single digits, while the price-to-sales ratio hovered around 0.8 times in late 2023 and early 2024. Analysts in those pieces describe the stock as a potential value opportunity, provided execution on specialty and biosimilar launches continues.

How the company makes money

Amneal generates most of its revenue from a broad portfolio of generic medicines across therapeutic areas such as central nervous system disorders, pain, and cardiovascular conditions, targeting both retail and institutional customers. The company also markets branded specialty drugs, including injectables and biosimilars, aimed at more complex indications with higher margin profiles.

Where the stock trades today

The shares of Amneal Pharmaceuticals (US03168L1052) last closed on Nasdaq at $16.21 on 06/18/2026, 16:00 ET, according to delayed quote data from market platforms.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.